小干扰RNA疗法用于高血压的管理和预防
Liwei Ren1,2, A H Jan Danser3,4
1Department of Pharmacy, The Second Clinical Medical College, The First Affiliated Hospital, Shenzhen People's Hospital, Jinan University, Southern University of Science and Technology), Shenzhen, China.
Current hypertension reports
|January 14, 2025
概括
小干扰RNA (siRNA) 针对肝血管酶原提供了一种新的长期抗高血压治疗方法. 这种方法可能会彻底改变血压管理,克服不坚持并显示与现有疗法相匹配的疗效.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
- 在RNA治疗方面,RNA疗法.
背景情况:
- 不遵守抗高血压药物是失控血压的主要原因.
- 氨酸-血管氨系统 (RAS) 在血压调节中起着至关重要的作用.
- 需要新的治疗策略来改善长期的血压管理.
研究的目的:
- 审查当前关于小干扰RNA (siRNA) 向肝脏血管新生素作为抗高血压治疗的知识.
- 评估基于siRNA的疗法的潜力,以克服血压控制方面的挑战.
主要方法:
- 审查现有的科学文献和临床试验数据.
- 对siRNA对血管酶因子合成的作用机制的分析.
- 对疗效和安全的临床前和临床证据的评估.
主要成果:
- 一次注射的血管激素原siRNA可以抑制RAS活性长达6个月.
- 临床前和临床研究表明,这种疗效与RAS阻断剂相当.
- 一期和二期试验证实了抗高血压的有效性和长期作用,具有类似于安慰剂的副作用.
- 目前正在开发REVERSIR技术,如果需要,可以快速逆转siRNA效应.
结论:
- ангиотензиноген siRNA 代表了一种潜在的革命性的抗高血压治疗,具有持久效果和改善的坚持性.
- siRNA作用的可逆性解决了在关键情况下的安全问题.
- 这种方法对管理高血压和降低心血管风险具有重大前景.
相关概念视频
02:30siRNA - Small Interfering RNAs
16.5K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.5K
02:30Small interfering RNAs (siRNA)
3.5K
3.5K
02:15Experimental RNAi
6.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.0K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
483
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
483
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
578
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
578